Ates Ilker, Sahin Hilal, Irham Lalu Muhammad, Yilmaz Serkan, Suzen Sinan
Faculty of Pharmacy, Department of Toxicology, Ankara University, Ankara, Türkiye.
Faculty of Medicine, Department of Medical Biology and Genetic, Atlas University, Istanbul, Türkiye.
Basic Clin Pharmacol Toxicol. 2025 Aug;137(2):e70082. doi: 10.1111/bcpt.70082.
A drug preferred for its antimalarial effect called hydroxychloroquine (HCQ) has long been used to manage and avoid malaria. Nevertheless, its exact mode of action is still unknown. HCQ works through a variety of strategies to influence distinct molecular and cellular pathways. Additionally, HCQ has been demonstrated to be an effective treatment for rheumatic conditions such as primary Sjögren's syndrome, rheumatoid arthritis, antiphospholipid syndrome and systemic lupus erythematosus. Despite being widely regarded as safe, HCQ has been known to cause adverse responses; thus, doctors should closely evaluate rheumatism patients before taking these medications. The current study aims to emphasize the potential side effects of treatment while supporting the clinical usage of HCQ for autoimmune disorders.
一种因其抗疟作用而备受青睐的药物——羟氯喹（HCQ），长期以来一直被用于防治疟疾。然而，其确切的作用方式仍不明确。HCQ通过多种策略来影响不同的分子和细胞途径。此外，HCQ已被证明是治疗风湿性疾病的有效药物，如原发性干燥综合征、类风湿性关节炎、抗磷脂综合征和系统性红斑狼疮。尽管HCQ被广泛认为是安全的，但已知它会引起不良反应；因此，医生在给风湿性疾病患者使用这些药物之前应进行密切评估。本研究旨在强调治疗的潜在副作用，同时支持HCQ在自身免疫性疾病中的临床应用。
